Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 2109 • ACR Convergence 2025
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Edgar Wiebe¹, Lien Meerkatt², Andriko Palmowski³, Zhivana Boyadzhieva⁴, Kerstin Rubarth⁵, Sandra Hermann¹, Burkhard Muche³, Gerhard Krönke⁶ and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Individuals with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are at increased risk for osteoporosis and fragility fractures due to long-term glucocorticoid (GC)…
Abstract Number: 0753 • ACR Convergence 2025
Incidence of Ischemic Vision Loss Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Mary Peng¹, Kylie Carlson², Sebastian E Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Ischemic vision loss affects up to one quarter of patients with giant cell arteritis (GCA). The incidence of ischemic vision loss among patients with…
Abstract Number: 1987 • ACR Convergence 2025
Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™
Shilpa Venkatachalam¹, Erik Stone², Ian Carroll³, angela Degrassi³, Shelley Fritz⁴ and David Curtis⁵, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Kalaheo, HI, ⁵Global Healthy Living Foundation, Meriden
Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory condition affecting individuals over 50, marked by bilateral shoulder and hip stiffness and pain. Its nonspecific symptoms…
Abstract Number: 0752 • ACR Convergence 2025
Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
Maite Silva-Diaz¹, Marta Domínguez-Álvaro², Rafael B. Melero-González³, Elisa Fernández-Fernández⁴, Jesús Alejandro Valero⁵, Ismael González⁶, Julio Sánchez Martín⁷, Javier Narváez⁸, Eva Galíndez Agirregoikoa⁹, Vicente Aldasoro Cáceres¹⁰, lydia Abasolo Alcazar¹¹, Javier Loricera¹², Noemí Garrido¹³, Santos Castañeda¹⁴, Carlota L Iñiguez¹⁵, Alicia Garcia¹⁶, Clara Molina Almela¹⁷, María Alcalde Villar¹⁸, Antonio Juan Mas¹⁹ and Ricardo Blanco²⁰, ¹Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Hospital Universitario Donosti, Donosti, Spain, ⁶Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁷Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁰Hospital Universitario de Navarra, Pamplona, Spain, ¹¹IdISSC. HCSC, Madrid, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁵Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ¹⁶Rheumatologist, La Laguna, Spain, ¹⁷Consorci Hospital General Universitari de València, Valencia, Spain, ¹⁸Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a chronic granulomatous vasculitis affecting medium- and large-sized arteries (1). The classic symptoms are cranial symptoms, including headache, jaw…
Abstract Number: 1910 • ACR Convergence 2025
Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
Julie Mouchet¹, Tim Nguyen², Valeria Jordan M.³, G S Ramakrishna⁴, Linda Grinnell-Merrick², Andrew Heaney⁵, Anushka Mitra Das⁵, Pooja Shah⁶ and Evi Zhuleku⁷, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁴Novartis Healthcare Private Limited, Hyderabad, India, ⁵Novartis Ireland Ltd, Dublin, Ireland, ⁶Cytel Inc, Cambridge, ON, Canada, ⁷Cytel Inc, Berlin, Germany
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions which predominantly affect individuals over the age of 50 years. The conditions…
Abstract Number: 0749 • ACR Convergence 2025
Prevalence and characteristics of subclinical Polymyalgia Rheumatica in patients with Giant Cell Arteritis
Javier Narváez¹, Paola Vidal-Montal², Martí Aguilar-Coll³, Montserrat Roig Kim⁴, Laia De Daniel Bisbe⁴, Monica Cubells⁵, Aina Fabregat⁶, Judith Palacios-Olid³, Pol Maymó-Paituvi⁴, Carmen Moragues³ and Joan Miquel Nolla⁴, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology. Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Hospital Universitari de Bellvitge, Barcelona, Spain, ⁶Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain
Background/Purpose: In clinical practice, 18F-FDG PET-CT often reveals findings suggestive of polymyalgia rheumatica (PMR) in patients with giant cell arteritis (GCA) who lack symptoms or…
Abstract Number: 1629 • ACR Convergence 2025
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Sebastian E Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian H Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Morristown, NJ, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…
Abstract Number: 0746 • ACR Convergence 2025
Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort
Fatima Hassan¹, Michael Putman² and Sebastian E Sattui³, ¹Medical College of Wisconsin, Menomonee Falls, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Frailty, a syndrome associated with decreased physiologic reserve, is associated with adverse outcomes. The prevalence and impact of baseline frailty on the risk of…
Abstract Number: 1627 • ACR Convergence 2025
A systematic literature review to inform the 2025 EULAR recommendations for management of Polymyalgia Rheumatica and Large Vessel Vasculitis: management of disease including relapse and complications
Mrinalini Dey¹, Durga Prasanna Misra², Alice Bartoletti³, Georgina Ducker⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ³ASST Gaetano Pini CTO, Cremona, Italy, ⁴Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: EULAR recommendations informing the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) were previously published separately in 2015 [1] and 2020 [2]…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
Abstract Number: 1619 • ACR Convergence 2025
Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
Gaston Ariel Ghio¹, Maria Gabriela Paz Machado², Evelin Encalada², Imma Perez Nadales², Georgina Salvador Alarcón², Elena Riera Alonso², manel pujol², Marta Pujol Teixidor² and Silvia Martinez Pardo², ¹Hospital Universitari Mùtua Terrassa, Terrassa, Catalonia, Spain, ²Hospital Universitari Mùtua Terrassa, Terrassa, Spain
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are chronic inflammatory disorders predominantly affecting patients over 50. Despite unclear etiopathogenesis, both conditions share central…
Abstract Number: 0349 • ACR Convergence 2025
Underrecognized Glucocorticoid-Induced Osteoporosis in a Polymyalgia Rheumatica Patient Cohort
katherine Loomba¹, Emily Campbell¹, Nisha Khubchandani¹, chih Fang¹, William Rigby² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth-Hitchcock, Norwich, VT
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…
Abstract Number: 1617 • ACR Convergence 2025
Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Erik Stone¹, Shilpa Venkatachalam², angela Degrassi³, Laura Stradford¹, Ambika Vartak⁴ and Shelley Fritz⁵, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Meriden, ⁵Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Polymyalgia rheumatica (PMR) is a commonly occurring inflammatory condition affecting older adults, primarily presenting with bilateral shoulder and hip stiffness. Despite its high prevalence…
Abstract Number: 1616 • ACR Convergence 2025
Short-Course Prednisone and Methotrexate in Polymyalgia Rheumatica: A Potential Therapeutic Approach
Edoardo Conticini¹, Silvia Grazzini¹, Raffaele Truscelli², Paolo Falsetti³, Luca Cantarini⁴ and Bruno Frediani⁴, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²University of Siena, Siena, Italy, ³Siena University Hospital, Siena, Italy, ⁴Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Despite being considered an easy-to-diagnose and easy-to-treat condition, the optimal treatment of PMR is far from being fully elucidated. Three recently published trials have…
Abstract Number: 1614 • ACR Convergence 2025
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
Alice Bartoletti¹, Georgina Ducker², Mrinalini Dey³, Durga Prasanna Misra⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Department of Rheumatology, ASST Gaetano Pini CTO, Milan, Italy, Milan, Lombardia, Italy, ²Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ³Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK, London, England, United Kingdom, ⁴Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) date back to 2015…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].